I have been practicing medicine for twenty-three years — in Nigeria, where I was trained and where I first understood that medicine is not merely a profession but a covenant, and in the United States, where I have spent years walking alongside patients on their health journeys. That experience has shaped every clinical decision I have made.

A deep commitment to accessible, compassionate care has guided my path — it is the reason I opened Primary Health Clinics of Mississippi, the reason I practice the way I do, and in no small part, the reason I said yes when Dr. Ashley Harris asked me to serve as Medical Director of The Skin Parlor™.

Healthcare works best when it reaches everyone. That is not a political statement. It is a medical one.

I want to begin there — with that conviction — because it informs everything I am about to share about GLP-1 receptor agonist therapy, metabolic medicine, and the community I have spent my career serving. The science matters enormously. But the science exists in service of people. And the people I treat deserve both the best available medicine and a physician who is genuinely invested in their wellbeing.

A Physician Formed by Two Worlds

I completed my medical training in Nigeria — a country where the practice of medicine demands a particular kind of resourcefulness, a particular kind of intimacy with patients, and a particular kind of humility before the complexity of the human body. Nigerian medical education is rigorous in ways that are difficult to overstate. You learn to diagnose with your hands and your eyes before you reach for a test. You learn to listen because listening is often the most diagnostic tool available. You learn that medicine, at its best, is a relationship.

When I came to the United States and completed my training here, I brought that formation with me. I pursued Internal Medicine and, subsequently, Obesity Medicine — a specialty I have practiced since 2019, and one that deserves far greater recognition for its depth and complexity. Obesity is not a lifestyle choice. It is not a failure of willpower. It is a chronic, multifactorial condition with genetic, hormonal, neurological, environmental, and socioeconomic dimensions. Treating it requires the same rigor, the same longitudinal commitment, and the same absence of judgment that we bring to any other chronic condition.

Every patient I have ever treated has been doing their best. My role is to give them better tools — and to stand beside them as they use them.

I have been practicing in Mississippi since 2006 — twenty years of building relationships, earning trust, and showing up for a community that deserves consistent, compassionate care. My flagship clinic is in Newton — a small, rural community in the heart of the state — and my second location opened in Meridian in January of 2026. People call me the Local Country Doctor, and I receive that name with genuine gratitude. It means I have earned trust. It means patients feel seen. It means that somewhere along the way, I stopped being just a physician and became something closer to a neighbor.

I have patients who travel from Texas, Florida, Georgia, Tennessee, Maine, Alabama, Louisiana, and beyond to see me — people who relocated years ago but have not found another physician they trust with their care. That is not something I take lightly. It is something I think about every single day.

Understanding GLP-1 and Metabolic Medications: The Science, Plainly Spoken

Glucagon-like peptide-1 — GLP-1 — is a hormone produced naturally in the gut in response to food intake. It was first identified in the 1980s, and for decades it was studied primarily in the context of type 2 diabetes management. What researchers discovered, over time, was that GLP-1 does far more than regulate blood sugar. It is, in the most precise sense of the word, a metabolic orchestrator.

GLP-1 receptor agonists — the class of medications that includes semaglutide and tirzepatide, among others — work by mimicking and amplifying the body's natural GLP-1 response. These are among the most studied options in this class, but they are not the only ones. Through our partnerships with compounding pharmacies and pharmaceutical providers, we have access to a range of medications that support metabolic health — and we select the right option based on each patient's individual history, goals, insurance coverage, and clinical profile. No single medication is right for every person, and part of our work is ensuring that the right tool is matched to the right patient.

Metabolic therapy does not override the body. It restores a conversation the body was already trying to have — one that obesity, insulin resistance, and chronic inflammation had disrupted.

First: appetite regulation at the neurological level. GLP-1 receptors are present not only in the pancreas and gut but in the brain — specifically in the hypothalamus and brainstem, regions that govern hunger, satiety, and reward-driven eating behavior. When GLP-1 receptor agonists bind to these central receptors, they reduce appetite signaling in ways that are fundamentally different from older weight loss medications. Patients do not simply feel less hungry. They report a quieting of what many describe as "food noise" — the persistent, intrusive preoccupation with food that characterizes the neurological experience of obesity. This is not willpower. This is neuroscience.

Second: gastric emptying. GLP-1 receptor agonists slow the rate at which the stomach empties its contents into the small intestine. This produces a prolonged sense of fullness after meals, reduces postprandial glucose spikes, and decreases the frequency and intensity of hunger signals between meals. For patients who have spent years eating in response to biological hunger signals they could not override through effort alone, this mechanism is genuinely life-altering.

Third: insulin secretion and glucagon suppression. In the pancreas, GLP-1 receptor agonists stimulate insulin release in a glucose-dependent manner — meaning they enhance insulin secretion when blood sugar is elevated but do not trigger hypoglycemia when glucose levels are normal. Simultaneously, they suppress glucagon, the hormone that signals the liver to release stored glucose. This dual action produces meaningful improvements in glycemic control, making these medications profoundly effective for patients with type 2 diabetes or prediabetes.

Fourth — and this is where the science becomes particularly compelling — cardiovascular and systemic benefits. Research has demonstrated that certain GLP-1 receptor agonists reduced the risk of major adverse cardiovascular events in patients with obesity and established cardiovascular disease, independent of weight loss. Subsequent research has suggested anti-inflammatory effects, potential hepatoprotective properties in non-alcoholic fatty liver disease, and emerging data on kidney protection. We are, in other words, not simply talking about weight loss medications. We are talking about a class of drugs that may fundamentally alter the trajectory of chronic disease.

It is also worth noting that GLP-1 receptor agonists are not the only tool in metabolic medicine. Depending on a patient's clinical picture, we may discuss other pharmacological options — including medications that work through different mechanisms, compounded formulations, or combination approaches. Our pharmaceutical partnerships give us access to a range of evidence-informed options, and the right choice is always determined by the individual patient — not by what is most available or most marketed.

The data is not subtle. Metabolic medicine has reached a paradigm shift — not in how we think about weight, but in how we understand metabolic disease itself.

Who Is a Candidate — and What the Conversation Actually Looks Like

In my clinic, the conversation about metabolic therapy begins long before a prescription is written. It begins with a comprehensive assessment — body composition analysis, metabolic panel, lipid profile, thyroid function, HbA1c, and a thorough review of the patient's medical history, current medications, and personal goals. It continues with an honest, unhurried conversation about what this therapy can and cannot do — and which specific approach is right for this particular person.

Candidacy for metabolic pharmacotherapy is evaluated on an individual basis. Clinical guidelines provide a framework — BMI thresholds, comorbidity considerations, contraindications — but those guidelines exist within the context of a human being, and that context matters enormously. Two patients with identical BMIs may be candidates for entirely different treatment approaches. That is why the assessment comes first, always.

I have patients who come to me having tried many approaches — dietary modification, structured exercise programs, behavioral therapy, previous pharmacotherapy — and who are ready for a new conversation. The biology of weight management is genuinely complex. It includes powerful adaptive mechanisms — shifts in resting metabolic rate, changes in appetite-regulating hormones, alterations in gut microbiome composition — that can make progress feel elusive despite real effort. These are not personal shortcomings. They are physiological realities that medicine can now meaningfully address.

When I prescribe GLP-1 therapy, I am not giving a patient a shortcut. I am giving them a physiological environment in which their efforts can finally produce the results they have always deserved.

I am also transparent about limitations and side effects — which vary by medication and by patient. For GLP-1 receptor agonists, the most common are gastrointestinal: nausea during dose escalation, which typically resolves, and occasional discomfort. There are important contraindications to review for certain medications, including personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. For other medication classes, the profile differs — which is precisely why a thorough intake and ongoing monitoring are non-negotiable parts of our program. I discuss all of this honestly, before a prescription is ever written.

And I discuss cost. Because in rural Mississippi, cost is never an abstraction.

Making Access a Priority

The cost of GLP-1 therapy remains a real consideration for many patients, and navigating insurance coverage, prior authorizations, and out-of-pocket costs can feel overwhelming. I believe that every patient who could benefit from this therapy deserves a clear path to it — and that finding that path is part of my job as their physician.

Expanding access to effective metabolic care is a goal I share with the broader medical community — and one I work toward every day in my practice.

This is the gap that drove my partnership with The Skin Parlor™. Dr. Ashley Harris and I share a foundational conviction: that access to quality medical care should not be determined by income. That the most vulnerable patients — those in rural communities, those without comprehensive insurance, those who have been historically underserved by the healthcare system — deserve the same standard of care as anyone else. Not a diminished version of it. The same.

Through the PHCM Metabolic Reset™ program in partnership with The Skin Parlor™, we make physician-guided metabolic care genuinely accessible. Most insurance plans cover the medical visit, while medication is self-pay. It is a deliberate approach to clear, responsible care — not a marketing consideration. Not a secondary concern. Non-negotiable.

Every patient in our program receives a comprehensive initial assessment, regular body composition tracking, medication review, and access to a physician who is genuinely invested in their outcomes.

Affordable does not mean inferior. It means we chose access over margin. Every time.

Why The Skin Parlor™ — and Why Now

When Dr. Ashley approached me about this partnership, I asked her one question: what is the vision? She told me she wanted to build a place where people could receive physician-guided metabolic care alongside aesthetic wellness — where the connection between how we feel in our bodies and how we present to the world was honored rather than compartmentalized. Where a woman could address her metabolic health and her skin health and her sense of self in a single, intentional space.

I said yes immediately.

Because in my twenty-three years of practice, I have watched patients lose significant weight and then struggle with the aesthetic consequences — skin laxity, changes in facial volume, the particular emotional complexity of a body that has transformed but does not yet feel like home. The integration of metabolic medicine and aesthetic care is not a luxury offering. It is a clinically coherent approach to whole-person wellness. The body does not experience its systems in isolation. Neither should its care.

Medicine that treats the whole person — metabolic health, aesthetic confidence, emotional well-being — is not a novel concept. It is simply good medicine, finally delivered in a space worthy of it.

Mississippi has one of the highest rates of metabolic disease in the United States. It also has a strong, resilient community of people who show up for their health when given the right environment and support. When patients have access to a physician who listens, a care plan that fits their life, and a space that feels welcoming — they thrive. That is what I have witnessed for twenty years. That is what drives this work.

I have spent a decade trying to change that, one patient at a time, in a small clinic in Newton, Mississippi. The Skin Parlor™ allows me to extend that work — to reach patients who might not walk through the door of a traditional medical clinic but who are ready, in a space that feels welcoming and affirming, to begin the conversation about their metabolic health.

A Final Word on What This Work Means

I want to close with something that does not appear in any clinical trial or pharmacological review — because it is the thing that matters most to me as a physician.

I have watched patients in this program experience meaningful, lasting change. Blood pressure normalizing. HbA1c values returning to healthy ranges. Sleep improving. Energy returning. I have watched people walk into my clinic months after starting treatment and describe, with a kind of quiet wonder, what it feels like to move through the world feeling strong, capable, and at home in their body.

That is not a side effect of the medication. That is a human being reclaiming their life. And there is no clinical outcome more significant than that.

Metabolic therapy is not a cure. It is not a guarantee. It is a tool — or more precisely, a set of tools — that, in the right hands and with the right support, can change the trajectory of a person's health in ways that were not possible a decade ago. I do not prescribe casually. I prescribe with the same rigor, the same longitudinal commitment, and the same genuine investment in outcomes that I bring to every aspect of my practice. And I choose the right medication for the right patient — not the most popular one, not the most marketed one. The right one.

If you have questions about whether the PHCM Metabolic Reset™ program is appropriate for you, I encourage you to begin the conversation. Not because I have a prescription ready. But because you deserve a physician who will take the time to understand your history, your goals, and your circumstances — and who will tell you the truth about what medicine can and cannot offer.

That has always been the kind of doctor I set out to be. It is the kind of care The Skin Parlor™ was built to deliver.